Literature DB >> 17283296

Results of a general hepatitis C lookback program for persons who received blood transfusions in a neonatal intensive care unit between January 1975 and July 1992.

Henry H Cagle1, Jack Jacob, Chriss E Homan, James L Williams, Carol J Christensen, Brian J McMahon.   

Abstract

OBJECTIVE: To notify persons who received a blood transfusion in a neonatal intensive care unit between January 1975 and July 1992 of their risk for hepatitis C infection and to encourage them to seek hepatitis C antibody testing.
DESIGN: Neonatal intensive care unit, blood bank, and public access records were queried to identify current mailing addresses and persons deceased. All persons were notified by letter.
SETTING: Anchorage, Alaska. PARTICIPANTS: Persons who received health care in an integrated health care system, the Alaska Native Medical Center, or in the private sector. Main Exposure Transfusion in the neonatal period. MAIN OUTCOME MEASURES: Prevalence of test results positive for the hepatitis C virus antibody and RNA and awareness of having received a blood transfusion in a neonatal intensive care unit.
RESULTS: Alaska Native Medical Center (n = 401) and private sector (n = 1396) persons were targeted for notification. Letters were mailed to 277 Alaska Native Medical Center (69%) and 374 private sector (27%) persons, with 151 (55%) and 65 (17%) screened for hepatitis C, respectively. Among those screened (n = 216), 7 (3%) were hepatitis C antibody positive, with 6 (<3%) also hepatitis C virus-RNA positive. Among 147 persons who responded, 75 (51%) were unaware they had received a transfusion.
CONCLUSIONS: Compared with the private sector, a higher proportion of persons were identified and tested from the integrated health care system and more than half of respondents were unaware of their transfusion history. It would be prudent to screen neonatal intensive care unit patients who received transfusions before July 1992 for hepatitis C virus infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283296     DOI: 10.1001/archpedi.161.2.125

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  5 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

2.  Hepatitis C Infection Among Hispanics in California.

Authors:  Catherine A Cummins; Erlyana Erlyana; Dennis G Fisher; Grace L Reynolds
Journal:  J Addict Dis       Date:  2015

3.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

4.  Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus.

Authors:  Dennis G Fisher; Kristen L Hess; Erlyana Erlyana; Grace L Reynolds; Catherine A Cummins; Todd A Alonzo
Journal:  Open Forum Infect Dis       Date:  2015-07-07       Impact factor: 3.835

5.  The Ethics of Repurposing Previously Collected Research Biospecimens in an Infectious Disease Pandemic.

Authors:  Benjamin E Berkman; Anna C Mastroianni; Leila Jamal; Coleman Solis; Holly A Taylor; Sara Chandros Hull
Journal:  Ethics Hum Res       Date:  2021-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.